Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Igen v. Roche

This article was originally published in The Gray Sheet

Executive Summary

Roche Diagnostics maintains that a judge's February ruling bars Igen from using its Origen biological detection technology and Roche's improvements, including the Elecsys lines of clinical diagnostic immunoassay analyzers and tests developed for those systems, in central labs, blood banks and hospitals. However, Igen disputes the claim, arguing that after termination of an existing license agreement, permitted by a Jan. 10 Maryland federal court jury verdict, the firm will be free to use the technology in Roche's fields as well as non-licensed fields (1"The Gray Sheet" Jan. 14, 2002, p. 31). Igen has notified Roche that the license terminates immediately once the final judgement is affirmed by the court of appeals. Roche expects the appeals process to continue until the second half of 2003...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT016218

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel